

S/N 10/542,914


PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Alfred Marchal	Examiner:	Valenrod, Yevgeny
Serial No.:	10/542,914	Group Art Unit:	1621
Filed:	March 7, 2006	Docket No.:	09997.0127USWO
Customer No.:	23552	Confirmation No.:	9556
Title:	USE OF A COMPOSITION COMPRISING VITAMIN K1 OXIDE OR A DERIVATIVE THEREOF FOR THE TREATMENT AND/OR THE PREVENTION OF MAMMAL DERMATOLOGICAL LESIONS		


---

DECLARATION OF DR. KARAVANI UNDER 35 U.S.C. § 1.132

1. I, Dr. Ilan Karavani, declare as follows:
  2. I am an expert in the field of the invention and am familiar with the specification and prosecution history of U.S. patent application serial no. 10/542,914 filed July 20, 2005. The 10/542,914 application is a national stage application of international application no. PCT/BE/04/0011 filed January 20, 2004.
  3. It is my understanding that the Applicant is required under 37 C.F.R. § 1.105 to provide copies of the studies referred to in my first declaration under 35 U.S.C. § 1.132 (filed April 10, 2007) at page 3, under the title "Pharmacological Aspects" lines 9-10 that have been published.
  4. Exhibit A is the Exhibit A that accompanied my declaration under 37 C.F.R. § 1.132 filed April 10, 2007. As explained in my declaration under 37 C.F.R. § 1.132 filed February 18, 2010, I was retained by the inventor, Dr. Alfred Marchal, as an expert to perform experimental studies for the assignee Auriga International. One of the studies I performed for the assignee was the study of Exhibit A entitled "Topical use of vitamin K versus vitamin K oxide: A clinical evaluation of postoperative bruising and edema." This study was
- 

transmitted to the assignee by me. It is my understanding that this study was not publicly disclosed prior to January 20, 2004.

5. As an expert for the assignee, experimental studies performed for the assignee were made available to me. All of the studies that I was referring to at lines 9-10 of the Pharmacological aspects section of Exhibit A were experimental studies performed by the assignee. These studies evaluated vitamin K1 oxide compared to vitamin K1 for treating bruising (ecchymosis). In these studies, cosmetic creams containing vitamin K oxide were found to be more topically active than cosmetic creams containing vitamin K. These studies were provided to me by the assignee in my capacity as an expert for the assignee and were kept confidential by both me and the assignee. It is my understanding that these studies have not been publicly disclosed.
6. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements are made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful and false statements may jeopardize the validity of the application or any patent issuing thereon.

  
\_\_\_\_\_  
Ilan Karavani, Ph.D.

Dated: 10/14/2010

U.S. Application No.: 10/542,914

**Listing of Exhibits**

Exhibit A: Topical use of vitamin K versus vitamin K oxide: A clinical evaluation of postoperative bruising and edema.